BWA
ANIK icon

Basecamp Wealth Advisors’s Anika Therapeutics ANIK Stock Holding History

Basecamp Wealth Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$673 Buy
46
+20
+77% +$296 ﹤0.01% 1595
2026
Q1 		$377 Buy
+26
New +$302 ﹤0.01% 1785

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Basecamp Wealth Advisors's ANIK Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Anika Therapeutics (ANIK) stake by 77% in Q2 2026, buying an estimated $296 and bringing the position to 46 shares worth $673. The position accounts for ﹤0.01% of the portfolio, ranked #1595.

Basecamp Wealth Advisors first reported a position in ANIK in Q1 2026 and has held it in 2 quarters since. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Basecamp Wealth Advisors held 46 shares of Anika Therapeutics worth $673 as of Q2 2026.
  • Basecamp Wealth Advisors bought 20 Anika Therapeutics shares in Q2 2026, an estimated $296.
  • Anika Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1595 holding.
  • Basecamp Wealth Advisors first reported a position in Anika Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.